✦ LIBER ✦

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

✍ Scribed by Younes, Anas; Connors, Joseph M; Park, Steven I; Fanale, Michelle; O'Meara, Megan M; Hunder, Naomi N; Huebner, Dirk; Ansell, Stephen M

Book ID: 121385360
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 211 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70501-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a Pivotal Phase II Study of B

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

✍ Younes, Anas (author);Gopal, Ajay K. (author);Smith, Scott E. (author);Ansell, S 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 173 KB

Results of a Pivotal Phase II Study of B

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

✍ Younes, Anas (author);Gopal, Ajay K. (author);Smith, Scott E. (author);Ansell, S 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 173 KB

A Phase 1/2 Single-Arm, Open-Label Study

A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results

✍ LaCasce, Ann; Sawas, Ahmed; Bociek, R. Gregory; Ansell, Stephen; Vose, Julie; O' 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Rilotumumab in combination with epirubic

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

✍ Iveson, Timothy; Donehower, Ross C; Davidenko, Irina; Tjulandin, Sergey; Deptala 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 339 KB